If you or a loved one have taken (or affected by) Xigduo XR after October 2014 please contact us today.

FREE CASE REVIEW

Xigduo XR Linked to Diabetic Ketoacidosis, Lactic Acidosis and Possible Kidney Failure

Type 2 diabetes patients have another potential drug to worry about in their fight against diabetes. While Xigduo has been prescribed to many patients to reduce blood sugar levels, it also carries the potential for the development of serious health conditions that can be deadly.

If you have taken or are currently taking Xigduo XR and have developed a serious condition or complications, you may be eligible for compensation.

What is Xigduo?

Released in October of 2014, Xigduo is manufactured by AstraZeneca and prescribed, along with diet and exercise, for the treatment of Type 2 diabetes. Made from a combination of dapagliflozin and metformin, Xigduo is very similar to Invokamet, another medication used in the treatment of Type 2 diabetes. Xigduo is the only SGLT2 inhibitor and metformin formulation approved by the FDA that can be prescribed in a single daily dose. Xigduo, like other SGLT2 inhibitors, helps to reduce blood sugar by preventing glucose reabsorption, while increasing glucose release in the kidneys. Excess blood sugar is eliminated through urination.

 

What are the risks?

Like other SGLT2 inhibitors, Xigduo carries risk factors for the development of diabetic ketoacidosis, a serious condition that can result in swelling of the brain tissue, coma and death. Because Xigduo also contains metformin, patients are also at risk for developing lactic acidosis, a condition in which lactic acid builds to toxic levels in the bloodstream that can result in death.

Dapagliflozin, a main ingredient of Xigduo, was originally denied approval by the FDA in 2012 based on concerns about its effect on the liver.

Additional risks include:

A warning was published by the FDA in May 2015 concerning the risks of the development of diabetic ketoacidosis in patients who took SGLT2 inhibitors such as Xigduo XR. In December of the same year, the FDA ordered a change in labeling for all SGLT2 inhibitor products to include a warning about ketoacidosis risk and the possibility of urinary tract infections.

  • Kidney stones
  • Electrolyte imbalances
  • Urinary tract infections
  • Kidney failure

What You Can Do Now

If you or a loved one have experienced diabetic ketoacidosis, lactic acidosis, kidney failure or any other issue related Xigduo XR, you could be eligible for compensation.

Get Your Free Case Review By a Top-Rated Lawyers

Helping the Injured has been linking consumers with credible law firms that handle specific case areas for over 25 years. Our partner attorneys have a documented track record with these drugs and the injuries associated with them. Your attorney will work with you on a contingency basis, meaning you won’t pay anything unless damages are recovered on your behalf.

Regardless of where you were administered Xigduo XR our team of Xigduo XR lawsuit attorneys can help as they serve all 50 states and Washington D.C. including: Alabama, Alaska, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, Washington D.C., West Virginia and Wisconsin.

Review My Case